Literature DB >> 14742572

Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.

Charlotte Larsson1, Jan Holmgren, Gunnar Lindahl, Charlotta Bergquist.   

Abstract

Intranasal immunization of mice with Rib, a cell surface protein of group B streptococcus (GBS), conjugated to or simply coadministered with the recombinant cholera toxin B subunit, induces systemic immunoglobulin G (IgG) and local IgA antibody responses and confers protection against lethal GBS infection. These findings have implications for the development of a human GBS vaccine.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14742572      PMCID： PMC321638          DOI： 10.1128/IAI.72.2.1184-1187.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  26 in total

1.  Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans.

Authors:  E L Johansson; L Wassén; J Holmgren; M Jertborn; A Rudin
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Quantitative determination of immunoglobulin G specific for group B streptococcal beta C protein in human maternal serum.

Authors:  Catherine S Lachenauer; Carol J Baker; Miriam J Baron; Dennis L Kasper; Claudia Gravekamp; Lawrence C Madoff
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

3.  Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice.

Authors:  S K Hunter; M E Andracki; A M Krieg
Journal:  Am J Obstet Gynecol       Date:  2001-11       Impact factor: 8.661

5.  Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.

Authors:  T Lagergard; J Shiloach; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

6.  Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.

Authors:  M R Wessels; L C Paoletti; D L Kasper; J L DiFabio; F Michon; K Holme; H J Jennings
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

7.  Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V.

Authors:  T Areschoug; M Stålhammar-Carlemalm; C Larsson; G Lindahl
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

8.  Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus.

Authors:  C J Baker; M A Rench; M S Edwards; R J Carpenter; B M Hays; D L Kasper
Journal:  N Engl J Med       Date:  1988-11-03       Impact factor: 91.245

9.  Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine.

Authors:  C Larsson; M Stålhammar-Carlemalm; G Lindahl
Journal:  Vaccine       Date:  1999-02-05       Impact factor: 3.641

10.  Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease.

Authors:  J M Musser; S J Mattingly; R Quentin; A Goudeau; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205
View more
  10 in total

1.  Variation in the number of tandem repeats and profile of surface protein genes among invasive group B Streptococci correlates with patient age.

Authors:  Yueh-Ren Ho; Chien-Ming Li; Hsin-Pi Su; Jane-Hong Wu; Yu-Ching Tseng; Yuh-Jyh Lin; Jiunn-Jong Wu
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

2.  The Impact of Circulating Antibody on Group B Streptococcus Intestinal Colonization and Invasive Disease.

Authors:  Michelle J Vaz; Sheryl A Purrier; Maryam Bonakdar; Anna B Chamby; Adam J Ratner; Tara M Randis
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

Review 3.  Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.

Authors:  Gunnar Lindahl; Margaretha Stålhammar-Carlemalm; Thomas Areschoug
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization.

Authors:  Jacqueline A Baker; Emma L Lewis; Leah M Byland; Maryam Bonakdar; Tara M Randis; Adam J Ratner
Journal:  Vaccine       Date:  2017-02-02       Impact factor: 3.641

Review 5.  Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.

Authors:  Michael S Bronze; James B Dale
Journal:  Am J Med Sci       Date:  2010-09       Impact factor: 2.378

6.  Population structure of human isolates of Streptococcus agalactiae from Dakar and Bangui.

Authors:  Mathieu Brochet; Elisabeth Couvé; Raymond Bercion; Jean-Marie Sire; Philippe Glaser
Journal:  J Clin Microbiol       Date:  2008-12-24       Impact factor: 5.948

7.  Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis.

Authors:  Constantine Bitsaktsis; Deepak B Rawool; Ying Li; Nitin V Kurkure; Bibiana Iglesias; Edmund J Gosselin
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

8.  Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model.

Authors:  Donna A Santillan; Karishma K Rai; Mark K Santillan; Yogita Krishnamachari; Aliasger K Salem; Stephen K Hunter
Journal:  Am J Obstet Gynecol       Date:  2011-06-15       Impact factor: 10.693

9.  Requirement for Cyclic AMP/Protein Kinase A-Dependent Canonical NFκB Signaling in the Adjuvant Action of Cholera Toxin and Its Non-toxic Derivative mmCT.

Authors:  Manuela Terrinoni; Jan Holmgren; Michael Lebens; Maximilian Larena
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

10.  Defining the remarkable structural malleability of a bacterial surface protein Rib domain implicated in infection.

Authors:  Fiona Whelan; Aleix Lafita; Samuel C Griffiths; Rachael E M Cooper; Jean L Whittingham; Johan P Turkenburg; Iain W Manfield; Alexander N St John; Emanuele Paci; Alex Bateman; Jennifer R Potts
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-09       Impact factor: 11.205
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.